Metabolic syndrome in infertile women with polycystic ovarian syndrome

ABSTRACT Objective : The aim of the present study was to determine the prevalence of metabolic syndrome (MS) in infertile Iranian women with polycystic ovary syndrome (PCOS) using the ATPIII criteria. Subjects and methods : In this cross-sectional study, 624 women with PCOS were enrolled at a tertiary referral center in Tehran, Iran, between April, 2012 and March, 2013. Diagnosis of MS was according to ATPIII criteria. Also, we divided PCOS patients into following two main groups: (i) with MS (n = 123) and (ii) without MS (n = 501), and then compared variables between two groups. Results : The mean age, body mass index (BMI) and waist circumference were 28.6 ± 4.3 years, 26.7 ± 3.7 kg/m2 and 85.2 ± 8.7 cm, respectively. The prevalence of MS was 19.7%. Our findings showed that age, BMI, waist circumference and all metabolic parameters were higher in PCOS women with MS than related values in those without MS. The most and least prevalent forms of MS were low level of high density lipoprotein-cholesterol (HDL-C) and hypertension, respectively. Conclusion : It seems the prevalence of metabolic syndrome in our country isn’t as high as western countries. The prevalence rate of MS increased with age and BMI. One of the major cardiovascular risk factors, low level of HDL-C, is the most prevalent metabolic abnormality in our participants.

[1]  J. Spence.  Faculty Opinions recommendation of Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2013 .

[2]  E. Diamanti-Kandarakis,et al.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. , 2012, Endocrine reviews.

[3]  J. Ordóñez‐Llanos,et al.  Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[5]  S. Bhattacharya.  Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  Dongzi Yang,et al.  Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. , 2009, European journal of endocrinology.

[7]  G. Azevedo,et al.  Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. , 2008, Fertility and sterility.

[8]  Y. Hong,et al.  The metabolic syndrome in young Korean women with polycystic ovary syndrome. , 2007, Diabetes research and clinical practice.

[9]  A. Mykletun,et al.  Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study , 2007, BMC public health.

[10]  G. Maciel,et al.  Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[11]  S. Chanprasertyothin,et al.  Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: Using the International Diabetes Federation criteria , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[12]  D. Cibula,et al.  Metabolic syndrome in young Czech women with polycystic ovary syndrome. , 2005, Human reproduction.

[13]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[14]  T. Kılıç,et al.  Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. , 2005, Human reproduction.

[15]  Cristina Bianchi,et al.  Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. , 2005, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[16]  E. Ford.  The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.

[17]  N. Goldenberg,et al.  Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. , 2003, Metabolism: clinical and experimental.

[18]  S. Heymsfield,et al.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. , 2003, Archives of internal medicine.

[19]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[20]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[21]  M. Trevisan,et al.  Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. , 1998, American journal of epidemiology.

[22]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[23]  G. Boden,et al.  Effects of Age and Body Fat Insulin Resistance in Healthy Men , 1993, Diabetes Care.

[24]  S. Haffner,et al.  Prospective analysis of the insulin-resistance syndrome (syndrome X). , 1992, Diabetes.

[25]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[26]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[27]  D. Ferriman,et al.  Clinical assessment of body hair growth in women. , 1961, The Journal of clinical endocrinology and metabolism.

[28]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2015 .

[29]  Enrico Carmina,et al.  Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. , 2012, Fertility and sterility.

[30]  D. Ehrmann,et al.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[31]  N. Napoli,et al.  Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. , 2006, European journal of endocrinology.

[32]  D. Power.  Standards of medical care in diabetes. , 2006, Diabetes care.

[33]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[34]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[35]  J. Nestler,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(4):1929–1935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1045 Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycysti , 2022 .